ERBB2 and breast cancer: Current treatments for HER2+ breast cancer include receptor tyrosine kinase inhibitors (Lapatinib and Afatinib, that target both EGFR and HER2; Neratinib, that only binds to HER2), which block intracellular kinase activity, antibodies targeting the extracellular domain and inhibiting HER2 dimerization (Trastuzumab, Pertuzumab) or antibodies combined with a microtubule de-polymerization agent (Trastuzumab Emtansine; T-DM1).